Laken Patricia Ann
Regis University, Denver, Colorado; Penrose-St Francis Medical Center, Colorado Springs, Colorado.
Adv Neonatal Care. 2016 Apr;16(2):135-42. doi: 10.1097/ANC.0000000000000254.
Infantile hemangiomas are complex benign vascular tumors that present after birth. Hemangioma lesions have a predictable course of growth, but little is understood about the mechanism behind their development. Infantile hemangiomas are considered proliferative lesions of the endothelial cells.
To effectively manage infants with infantile hemangiomas, a clear understanding of the pathogenic pathways is important and can assist the healthcare provider with effective treatment. This understanding will facilitate a relationship of support with the families of affected infants.
METHODS/SEARCH STRATEGIES: EBSCO host and Ovid database search for key words of infantile hemangiomas, propranolol, vascular lesion, and proliferative lesion was utilized. Articles on pathophysiology along with recent research studies were include in the search.
FINDINGS/RESULTS: The use of propranolol is a recent development in the treatment of infantile hemangiomas, which has shown a high rate of response in decreasing the size and reducing the potential for life-long complications. Different studies have shown the same success rate with the use of propranolol but with different variables.
As a healthcare team member, better identification and customized care of these patients can reduce the rare but devastating complications of infantile hemangiomas.
Future research can help identify the most effective dose and course of propranolol administration.
婴儿血管瘤是出生后出现的复杂良性血管肿瘤。血管瘤病变有可预测的生长过程，但对其发展背后的机制了解甚少。婴儿血管瘤被认为是内皮细胞的增殖性病变。
为了有效治疗患有婴儿血管瘤的婴儿，清楚了解致病途径很重要，这有助于医疗服务提供者进行有效治疗。这种了解将促进与受影响婴儿家庭的支持关系。
方法/搜索策略：利用EBSCOhost和Ovid数据库搜索婴儿血管瘤、普萘洛尔、血管病变和增殖性病变的关键词。搜索中纳入了关于病理生理学的文章以及近期的研究。
普萘洛尔的使用是婴儿血管瘤治疗中的一项新进展，在减小血管瘤大小和降低终身并发症可能性方面显示出高有效率。不同研究显示使用普萘洛尔的成功率相同，但存在不同变量。
作为医疗团队成员，更好地识别和定制这些患者的护理可以减少婴儿血管瘤罕见但严重的并发症。
未来研究有助于确定普萘洛尔给药的最有效剂量和疗程。
